57th ASH Annual Meeting and Exposition (December 5-8, 2015): 652. Myeloma: Pathophysiology and Pre-Clinical Studies, excluding Therapy: Poster II

Myeloma: Pathophysiology and Pre-Clinical Studies, excluding Therapy Oral and Poster Abstracts
Poster

Hall A, Level 2 (Orange County Convention Center)

A New Class of T-Cell Bispecific Antibodies for the Treatment of Multiple Myeloma, Binding to B Cell Maturation Antigen and CD3 and Showing Potent, Specific Antitumor Activity in Myeloma Cells and Long Duration of Action in Cynomolgus Monkeys

Minh Diem Vu, PhD¹^*, Samuel Moser, MSc²^*, Camille Delon, MSc²^*, Melanie Latzko, MSc²^*, Reto Gianotti, MSc²^*, Remo Lüoend, BSc²^*, Chloé Friang, MSc²^*, Ramona Murr, MSc²^*, Lydia Jasmin Duerner, PhD²^*, Tina Weinzierl, PhD²^*, Tanja Fauti, PhD²^*, Marina Bacac, PhD²^*, Oliver Ast, PhD²^*, Anne Freimoser-Grundschober, PhD²^*, Tea Rodriguez Diaz, MSc²^*, Jörg Zielonka, PhD²^*, Erwin van Puijenbroek, PhD²^*, Ralf Hosse, PhD²^*, Peter Bruenker, PhD²^*, Ekkehard Mössner, PhD²^*, Christian Klein, PhD², Pablo Umaña, PhD² and Klaus Strein, MD, PhD¹^*

¹EngMab AG, Wilen, Switzerland
²Roche Innovation Center Zurich, Schlieren, Switzerland

2999

BI 836909, a Novel Bispecific T Cell Engager for the Treatment of Multiple Myeloma Induces Highly Specific and Efficacious Lysis of Multiple Myeloma Cells in Vitro and Shows Anti-Tumor Activity in Vivo

Susanne Hipp, PhD¹^*, Petra Deegen²^*, Joachim Wahl, PhD²^*, Diann Blanset, PhD³^*, Oliver Thomas²^*, Benno Rattel, PhD²^*, Paul Adam, PhD¹^* and Matthias Friedrich, PhD²^*

¹Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria
²Amgen Research (Munich) GmbH, Munich, Germany
³Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT

3000

A Novel Agent SL-401 Triggers Anti-Myeloma Activity By Targeting Plasmacytoid Dendritic Cells: Implications for a Novel Immune-Associated Mechanism

Arghya Ray, PhD¹, Deepika Sharma DAS, PhD¹^*, Yan Song, Ph.D¹^*, Vincent Macri, MA²^*, Christopher L. Brooks, PhD², Eric K. Rowinsky, MD²^*, Paul G. Richardson, MD³, Dharminder Chauhan, PhD¹ and Kenneth C Anderson, MD⁴

¹The LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
²Stemline Therapeutics, Inc., New York, NY
³Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
⁴LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA

3001

Mapping the Impact of Proteasome Inhibitor Therapy on the Immunopeptidome of Multiple Myeloma: Mass Spectrometry Identifies Robust Targets for T Cell Immunotherapy

Daniel Johannes Kowalewski¹^*, Simon D. Walz^1,2^*, Linus Backert³^*, Heiko Schuster¹^*, Susanne M. Rittig, MD²^*, Katja C. Weisel²^*, Helmut R Salih, MD^2,4, Lothar Kanz, MD², Hans-Georg Rammensee, PhD¹^*, Stefan Stevanovic, PhD¹^* and Juliane S Stickel, MD²^*

¹Department of Immunology, Interfaculty Institute of Cell Biology, University of Tübingen, Tuebingen, Germany
²Department of Hematology and Oncology, University of Tuebingen, Tuebingen, Germany
³Applied Bioinformatics, Center for Bioinformatics and Department of Computer Science, University of Tuebingen, Tuebingen, Germany
⁴Clinical Collaboration Unit Translational Immunology, German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Partner site Tuebingen, Tuebingen, Germany

3002

T Cell Receptor Gene Therapy Targeting the Intracellular Transcription Factor Bob1 for the Treatment of Multiple Myeloma and Other B Cell Malignancies

Lorenz Jahn¹^*, Renate S. Hagedoorn¹^*, Pleun Hombrink, PhD²^*, Michel G.D. Kester¹^*, Dirk M. van der Steen¹^*, Chopie Hassan³^*, Marjolein P. Schoonakker¹^*, Erwin van der Pijl¹^*, Peter A. van Veelen, PhD⁴^*, J.H. Frederik Falkenburg, MD, PhD¹ and Mirjam H.M. Heemskerk, PhD¹

¹Department of Hematology, Leiden University Medical Center, Leiden, Netherlands
²Department of Hematopoiesis, Sanquin Research, Amsterdam, Netherlands
³Department of Immunohematology and Blood Transfusion, Leiden University Medical Center, Leiden, Netherlands
⁴Center for Proteomics and Metabolomics, Leiden University Medical Center, Leiden, Netherlands

3003

IKZF1 Mutation Mediate Resistance to IMiDs in Human Hematopoietic Stem Cells

Shirong Li, PhD¹^*, Jing Fu, PhD¹^*, Jing Wu, MD, PhD^1,2^*, Markus Y Mapara, MD, PhD¹ and Suzanne Lentzsch, MD, PhD¹

¹Division of Hematology/Oncology, Columbia University, New York, NY
²Jilin University, Changchun, China

3004

Novel Patient Derived Multiple Myeloma Model Reflects Sensitivity Towards Anticancer Treatment in Multiple Myeloma Patients

Julia B. Schueler, DVM, PhD¹, Dagmar Wider²^*, Kerstin Klingner¹^*, Gabrielle Melanie Siegers, PhD³, Annette M May, MD⁴^*, Johannes M. Waldschmidt, MD²^*, Alexander Keller, MD²^*, Justus Duyster, MD²^*, Ralph M. Waesch, MD² and Monika Engelhardt, MD²

¹Oncotest GmbH, Freiburg, Germany
²Department of Hematology, Oncology and Stem Cell Transplantation, University of Freiburg Medical Center, Freiburg, Germany
³Department of Oncology, University of Alberta, Edmonton, Canada
⁴Institute of Pathology, University of Freiburg Medical Center, Freiburg, Germany

3005

Interfering with Arginine Metabolism As a New Treatment Strategy for Multiple Myeloma

Bjoern Jacobi, MD¹^*, Lea Stroeher, MS¹^*, Nadine Leuchtner¹^*, Hakim Echchannaoui, PhD¹^*, Alexander Desuki, MD¹^*, Lara Kuerzer¹^*, Alice Habermeier²^*, Edite Antunes¹^*, Eva Amann¹^*, John Bomalaski, MD³^*, Closs Ellen, PhD, Prof.²^*, Matthias Theobald, MD, PhD⁴ and Markus Munder, MD¹^*

¹Department of Hematology, Oncology and Pneumology, University Medical Center of the Johannes Gutenberg-University Mainz, Mainz, Germany
²Department of Pharmacology, University Medical Center of the Johannes Gutenberg-University Mainz, Mainz, Germany
³Polaris Pharmaceuticals, Inc.,, San Diego, CA
⁴University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany

3006

Stratification of Multiple Myeloma Patients Based on Ex Vivo Drug Sensitivity and Identification of New Treatments for Patients with High-Risk Relapsed/Refractory Disease

Muntasir Mamun Majumder, MSc, MPharm¹^*, Raija Silvennoinen, MD^2,3^*, Pekka Anttila, MD⁴^*, David Tamborero, PhD⁵^*, Samuli Eldfors, MSc¹^*, Juha Lievonen, MD⁴^*, Riikka J Karjalainen¹^*, Heikki Kuusanmäki, MSc¹^*, Alun Parsons¹^*, Minna Suvela¹^*, Kimmo Porkka, MD, PhD^4,6 and Caroline Heckman¹

¹Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland
²Department of Hematology, Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland
³Kuopio University Hospital, Department of Internal Medicine, Kuopio, Finland
⁴Department of Hematology, Helsinki University Hospital Comprehensive Cancer Center and University of Helsinki, Helsinki, Finland
⁵Research Unit on Biomedical Informatics, Department of Experimental and Health Sciences, Universitat Pompeu Fabra, Barcelona, Spain
⁶Hematology Research Unit Helsinki, Department of Medicine, University of Helsinki and Helsinki University Central Hospital (HUCH), Helsinki, Finland

3007

Concurrent Inhibition of Pim and Akt Pathways with Pim447 and Afuresertib Activates FOXO3a and Depletes c-Myc to Induce Synergistic Cell Death in Multiple Myeloma

Niamh Keane, MB BCh MRCPI¹^*, Mairead Reidy, PhD²^*, Alessandro Natoni, PhD²^* and Michael O'Dwyer, MD, FRCPI, FRCPath¹

¹Department of Hematology, National University of Ireland Galway, Galway, Ireland
²Biosciences, National University of Ireland Galway, Galway, Ireland

3008

Targeting PYK2 Mediates Microenvironment-Specific Myeloma Cell Death

Mark B Meads, PhD¹^*, Bin Fang, PhD²^*, Linda Mathews¹^*, Jennifer Gemmer, MS¹^*, Liang Nong, MD¹^*, Ismael Rosado-Lopez¹^*, Tuan Nguyen¹^*, Jennifer E. Ring³^*, William Matsui, MD⁴, Robert MacLeod, PhD⁵^*, David T. Weaver, PhD³, Jonathan A. Pachter, PhD³^*, Lori A. Hazlehurst, PhD⁶, John M. Koomen, PhD²^* and Kenneth H. Shain, MD, PhD¹

¹Malignant Hematology, Moffitt Cancer Center, Tampa, FL
²Proteomics, Moffitt Cancer Center, Tampa, FL
³Verastem, Inc., Needham, MA
⁴Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD
⁵Antisense Drug Discovery, Isis Pharmaceuticals, Inc., Carlsbad, CA
⁶Molecular Oncology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL

3009

Mechanism Study of Matrix Metalloproteinase 13 Effects on Osteoclast Activation and Lytic Bone Lesions in Multiple Myeloma

Jing Fu, PhD¹^*, Shirong Li, PhD¹^*, G. David Roodman, MD, PhD², Markus Mapara, MD, PhD¹, Stephen J. Weiss, MD³ and Suzanne Lentzsch, MD, PhD¹

¹Division of Hematology/Oncology, Columbia University, New York, NY
²Medicine/Hematology-Oncology, Indiana University, Indianapolis, IN
³University of Michigan, Ann Arbor, MI

3010

RNA Polymerase I Inhibition with CX-5461 As a Novel Strategy to Target MYC in Multiple Myeloma

Hans Lee, M.D.¹, Hua Wang, Ph.D.¹^*, Heather Lin, M.S.²^*, Veera Baladandayuthapani, Ph.D.²^*, Jin He¹^*, Richard Julian Jones, Ph.D.¹, Isere Kuiatse, Ph.D.¹^*, Dongmin Gu, M.D., Ph.D.¹, Zhiqiang Wang, PhD¹^*, Sean O'Brien, Ph.D.³^*, Jonathan J Keats, Ph.D.⁴, Jing Yang, PhD¹, Richard Eric Davis, M.D.¹^* and Robert Z. Orlowski, Ph.D., M.D.^1,5

¹Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX
²Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX
³Senhwa Biosciences, Inc, San Diego, CA
⁴Translational Genomics Research Institute, Phoenix, AZ
⁵Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX

3011

Fc Receptor Targeting Reduces Bone Disease in a Pre-Clinical Model of Multiple Myeloma

Mark T Williams, BSc Hons, PhD¹^*, Katya Thümmler, Ph.D¹^*, Susan Kitson, Bsc Hons¹^*, Richard Soutar, MD, Ph.D²^* and Carl S Goodyear, BSc Hons, PhD¹^*

¹Institute for Infection, Immunity and Inflammation, University of Glasgow, Glasgow, United Kingdom
²Beatson West of Scotland Cancer Centre, Gartnavel Hospital, Glasgow, United Kingdom

3012

Hypoxia-Inducible Factor (HIF)-1alpha Inhibition in Myeloma Cells Significantly Increases the Anti-Myeloma Effect of Lenalidomide in Vivo

Paola Storti, PhD¹^*, Valentina Marchica¹^*, Denise Toscani, PhD¹^*, Irma Airoldi, PhD²^*, Sophie Maiga, PhD³^*, Marina Bolzoni, PhD¹^*, Nicoletta Campanini⁴^*, Eugenia Martella, MD⁴^*, Cristina Mancini, MD⁴^*, Valentina Ferri^1,5^*, Gaetano Donofrio, PhD⁶^*, Martine Amiot, PhD⁷^*, Franco Aversa, MD^1,8^* and Nicola Giuliani, MD, PhD^1,8

¹Department of Clinical and Experimental Medicine, University of Parma, Parma, Italy
²Laboratorio di Oncologia, Istituto Giannina Gaslini, Genova, Italy
³Inserm 892 Nantes University Hospital, Nantes, France
⁴Pathology, Azienda Ospedaliero-Universitaria di Parma, Parma, Italy
⁵University of Insubria, Varese, Italy
⁶Department of Medical-Veterinary Science, University of Parma, Parma, Italy
⁷INSERM UMR-892, CHU, Nantes, France
⁸Hematology, Azienda Ospedaliero-Universitaria di Parma, Parma, Italy

3013

Loop Regulation Between microRNAs and Epigenetics Underlie microRNA Dysregulation in Multiple Myeloma and Is Associated with the Disease Progression

Kei Kimura¹^*, Yuko Kuroda¹^*, Yuta Masuda¹^*, Arito Yamane²^*, Hikaru Hattori³^*, Kenichi Tahara, MD⁴^*, Ayaka Kaneko¹^*, Itsumi Suda¹^*, Noriyuki Takahashi¹^*, Nanami Gotoh¹^*, Kie Nagai¹^*, Tomomi Nagashima¹^*, Takayuki Saitoh, MD, PhD¹^*, Hirono Iriuchishima, MD, PhD⁴^*, Makiko Takizawa, PhD, MD⁴^*, Hiromi Koiso⁴^*, Takuma Ishizaki⁴^*, Takeki Mitsui⁴^*, Hiroaki Shimizu, M.D., PhD.⁵^*, Akihiko Yokohama, MD, PhD⁶, Norifumi Tsukamoto, MD, PhD⁵, Tetsuhiro Kasamatsu¹^*, Yusuke Minato, PhD⁷^*, Yoshihisa Nojima⁴^*, Hirokazu Murakami, MD¹ and Hiroshi Handa, MD, PhD⁴

¹Department of Laboratory Science, Gunma University Graduate School of Health Sciences, Gunma, Japan
²Department of Molecular Pharmacology and Oncology, Gunma University Graduate School of Medicine, Gunma, Japan
³Nagoya University Hospital, Aichi, Japan
⁴Department of Medicine and Clinical Science, Gunma University Graduate School of Medicine, Gunma, Japan
⁵Oncology Center, Gunma University Hospital, Gunma, Japan
⁶Blood Transfusion Service, Gunma University Hospital, Gunma, Japan
⁷Department of Virology and Preventive Medicine, Gunma University, Gunma, Japan

3014

Combination of Anti-PD-L1 Antibody with IMiD® Immunomodulatory Drugs, HDAC Inhibitor ACY-1215, Bortezomib, or Toll-like Receptor 9 Agonist Enhances Anti-Tumor Immunity and Cytotoxicity in Multiple Myeloma

Arghya Ray, PhD¹, Deepika Sharma DAS, PhD¹^*, Yan Song, Ph.D¹^*, Dharminder Chauhan, PhD¹ and Kenneth C Anderson, MD²

¹The LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
²LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA

3015

MOR202, a Human Anti-CD38 Monoclonal Antibody, Mediates Potent Tumoricidal Activity In Vivo and Shows Synergistic Efficacy in Combination with Different Antineoplastic Compounds

Rainer Boxhammer^*, Johannes Weirather, PhD^*, Stefan Steidl, PhD^* and Jan Endell, PhD^*

MorphoSys AG, Martinsried/Planegg, Germany

3016

NEOD001 Specifically Binds Aggregated Light Chain Infiltrates in Multiple Organs from Patients with AL Amyloidosis and Promotes Phagocytic Clearance of AL Aggregates in Vitro

Wagner Zago^*, Mark Renz^*, Ronald Torres^*, Philip J. Dolan^*, Robin M. Barbour^*, Joshua R. Salmans^*, Paul J. Shughrue^*, Dale Schenk^* and Gene G. Kinney^*

Prothena Biosciences Inc, South San Francisco, CA

3017

Selinexor Is an Effective Cancer Treatment in Hypoxic Conditions and Synergizes with Proteasome Inhibitors to Treat Drug Resistant Multiple Myeloma

Barbara Muz, PhD, MSc¹, Feda Azab, BPharm²^*, Pilar De La Puente, PhD¹, Yosef Landesman, PhD³^* and Abdel Kareem Azab, BPharm, PhD¹

¹Department of Radiation Oncology, Cancer Biology Division, Washington University in Saint Louis School of Medicine, Saint Louis, MO
²Washington University In St. Louis, Saint Louis, MO
³Karyopharm Therapeutics Inc., Newton, MA

3018

The Src Inhibitor AZD0530 Prevents the Development of Osteolytic Bone Disease in Multiple Myeloma

Roy Heusschen, PhD¹^*, Joséphine Muller, MSc¹^*, Marilène Binsfeld, MSc¹^*, Erwan Plougonven, PhD²^*, Nadia Mahli, BSc¹^*, Geert Carmeliet, MD, PhD³^*, Angélique Léonard, PhD²^*, Martine Cohen-Solal, MD, PhD⁴^*, Karin Vanderkerken, PhD⁵, Yves Beguin, MD, PhD^1,6, Eline Menu, PhD⁵^* and Jo Caers, MD, PhD^1,6^*

¹Laboratory of Hematology, GIGA-I3, University of Liège, Liège, Belgium
²PEPs (Products, Environment, Processes), Department of Chemical Engineering, University of Liège, Liège, Belgium
³Laboratory of Clinical and Experimental Endocrinology, Department of Clinical and Experimental Medicine, KU Leuven, Leuven, Belgium
⁴Department of Rheumatology, INSERM-UMR 606, University of Paris-Diderot, Paris, France
⁵Myeloma Center Brussels, Department of Hematology and Immunology, Vrije Universiteit Brussel, Brussels, Belgium
⁶Division of Hematology, Department of Medicine, University and CHU of Liège, Liège, Belgium

3019

Growth Inhibition and Synergistic Induction of Apoptosis By Synthetic Mir-125b-5p Mimics and Myc-Targeting Agents in Human Myeloma Cell Lines

Lavinia Biamonte, PhD¹^*, Cinzia Federico, PhD²^*, Eugenio Morelli, MD³^*, Emanuela Leone, PhD¹^*, Maria Eugenia Gallo Cantafio, PhD¹^*, Maria Teresa Di Martino³^*, Nicola Amodio, PhD³^*, Marco Rossi, MD⁴^*, Antonino Neri, Pr, MD⁵, Pierosandro Tagliaferri, MD⁶^* and Pierfrancesco Tassone, MD⁶^*

¹Department of experimental and clinical medicine, Magna Graecia University of Catanzaro, Catanzaro, Italy
²Magna Graecia University of Catanzaro, Catanzaro, Italy
³Department of Experimental and Clinical Medicine, University Magna Graecia of Catanzaro, Catanzaro, Italy
⁴Magna Graecia University, catanzaro, Italy
⁵Department Medical Sciences, Hematology 1 CTMO, University of Milan, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy
⁶Salvatore Venuta Campus, Magna Graecia University, Catanzaro, Italy

3020

Identification of Biomarkers Associated with MAF-Mediated Resistance to Proteasome Inhibitors in t(14;16) Multiple Myeloma

Ya-Wei Qiang, Shiqiao Ye, PhD, BSc, MSc^*, Ricky D Edmondson, Ph.D.^*, Yuhua Huang^*, Sarah K. Johnson, PhD, Caleb K. Stein, MS^*, Bart Barlogie, MD, PhD, Joshua Epstein, DSc, Gareth J Morgan, MD PhD and Faith E Davies, MD

Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, AR

3021

Pharmacogenomics of Bortezomib in Multiple Myeloma Patients Reveals That the Ubiquitin Ligase SCF-Skp2 Promotes Drug Resistance

James J. Driscoll, MD, PhD^1,2^* and Ehsan Malek, MD³

¹The Vontz Center for Molecular Studies, University of Cincinnati, Cincinnati, OH
²University of Cincinnati, Cincinnati, OH
³Division of Hematology and Oncology, Case Western Reserve University, Cleveland, OH

3022

Antagonizing HDAC6 Activity: A New Strategy to Maximize the Anti-Myeloma Effects of BET Inhibition

Jennifer S. Carew, Ph.D.¹, Claudia M. Espitia²^*, Weiguo Zhao³^*, Valeria Visconte, PhD¹^*, Kevin R. Kelly, MD, PhD⁴ and Steffan T. Nawrocki, Ph.D.⁵

¹Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
²University of Texas Health Science Center at San Antonio, CTRC Institute for Drug Development, San Antonio
³CTRC Institute for Drug Development University of Texas Health Science Center at San Antonio, San Antonio, TX
⁴University of Southern California Keck School of Medicine, Los Angeles, CA
⁵CTRC Institute for Drug Development, University of Texas Health Science Center at San Antonio, San Antonio, TX

3023

YM155 Exerts Potent Cytotoxic Activity Against Quiescent (G0/G1) Multiple Myeloma and Bortezomib Resistant Cells Via Inhibition of Mcl-1 and Survivin

Miyuki Ookura, MD¹^*, Tatsuya Fujii²^*, Shinji Kishi, MD, PhD¹, Hiroko Shigemi, MD, PhD¹^*, Naoko Hosono, MD, PhD.¹^*, Takahiro Yamauchi, MD, PhD¹, Takanori Ueda, MD, PhD¹ and Akira Yoshida, MD, PhD³

¹Department of Hematology and Oncology, University of Fukui, Fukui, Japan
²Medical Department, University of Fukui, Fukui, Japan
³Department of Cancer Pharmacology, Faculty of Pharmaceutical Science, International University of Health and Welfare, Tochigi, Japan

3024

The Phenotype of Natural Killer (NK) Cells in Multiple Myeloma (MM) Patients: Impact on Ex Vivo Responsiveness to the Anti-SLAMF7 Antibody, Elotuzumab

Tatiana Pazina, MS, BS¹^*, Alexander MacFarlane, PhD¹^*, Ashley Mentik-James, PhD¹^*, Clinton Yam, MBBS², Rebecca Kotcher, BA³^*, Kerry S. Campbell, PhD, BSPharm¹^* and Adam D. Cohen, MD³

¹Fox Chase Cancer Center, Philadelphia, PA
²Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA
³Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA

3025

Pharmacokinetics and Biodistribution of Locked Nucleic Acid (LNA)-Mir-221 Inhibitor: A New Promising Anti-Myeloma Agent

Maria Eugenia Gallo Cantafio, PhD¹^*, Annamaria Gulla, MD^2,3^*, Nicola Amodio, PhD⁴^*, Emanuela Leone, PhD¹^*, Eugenio Morelli, MD⁴^*, Lavinia Biamonte, PhD¹^*, Antonino Neri, Pr, MD⁵, Pierosandro Tagliaferri, MD²^*, Pierfrancesco Tassone, MD²^* and Maria Teresa Di Martino⁴^*

¹Department of experimental and clinical medicine, Magna Graecia University of Catanzaro, Catanzaro, Italy
²Salvatore Venuta Campus, Magna Graecia University, Catanzaro, Italy
³Jerome Lipper Multiple Myeloma Disease Center, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA
⁴Department of Experimental and Clinical Medicine, University Magna Graecia of Catanzaro, Catanzaro, Italy
⁵Department Medical Sciences, Hematology 1 CTMO, University of Milan, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy

See more of: Myeloma: Pathophysiology and Pre-Clinical Studies, excluding Therapy
See more of: Oral and Poster Abstracts

<< Previous Session | Next Session >>

^*signifies non-member of ASH